Response to nivolumab as an immune checkpoint inhibitor rechallenge for esophageal squamous cell carcinoma with PD-L1 amplification: a case report
Hiroyuki Kodama, Toshiki Masuishi, Yasunobu Ishizuka, Tomoki Sakakida, Kazunori Honda, Yukiya Narita, Hiroya Taniguchi, Shigenori Kadowaki, Masashi Ando, Waki Hosoda, Kei Muro · 2026
Read Response to nivolumab as an immune checkpoint inhibitor rechallenge for esophageal squamous cell carcinoma with PD-L1 amplification: a case report by Hiroyuki Kodama, Toshiki Masuishi, Yasunobu Ishizuka, Tomoki Sakakida, Kazunori Honda, Yukiya Narita, Hiroya Taniguchi, Shigenori Kadowaki, Masashi Ando, Waki Hosoda, Kei Muro (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13272978.txt.
Description
Hiroyuki Kodama leads a 2026 case report of a 61-year-old man with esophageal cancer who responded again to an immune therapy he had received before. His cancer, a squamous cell type of the food pipe, had returned in neck lymph nodes after surgery, chemotherapy, radiation, and maintenance immune therapy. Later chemotherapy lines failed.
Gene profiling showed extra copies of the PD-L1 gene, with a copy gain of 8, and tissue tests showed high PD-L1 levels. Doctors restarted nivolumab 8.8 months after the first immune therapy ended. The tumor shrank partly after 3.1 months, though it grew again after 5 months. The authors suggest PD-L1 gene gain may help predict rechallenge benefit.
Catalog record
| CREATOR | Hiroyuki Kodama, Toshiki Masuishi, Yasunobu Ishizuka, Tomoki Sakakida, Kazunori Honda, Yukiya Narita, Hiroya Taniguchi, Shigenori Kadowaki, Masashi Ando, Waki Hosoda, Kei Muro |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25110 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |